London’s iconic red buses and public transport in other British cities will carry banner adverts featuring the Arabic phrase “Subhan Allah” (Glory be to God) in a bid to encourage British Muslims to support Syrian war victims.
The posters will appear on hundreds of buses during Ramadan, which begins at sunrise on June 6 and lasts until July 7, the Daily Mail reported.
The start of the campaign will begin a month after London elected the first Muslim mayor of a major Western city, Labour’s Sadiq Khan – who, coincidentally, is the son of a bus driver.
Islamic Relief, a Muslim charity, is funding the campaign, which will be rolled out in London, Manchester, Birmingham and Bradford.
Organizers hope it will present Islam in a positive way and encourage British Muslims to donate to humanitarian efforts for victims of the ongoing war in Syria.
“In a sense this could be called a climate change campaign because we want to change the negative climate around international aid and around the Muslim community in this country,” director Islamic Relief, Imran Madden said.
“International aid has helped halve the number of people living in extreme poverty in the past 15 years, and British Muslims are an incredibly generous community who give over £100 million to international aid charities in Ramadan.” (IANS)
November 7, 2017: Actor Sidharth Malhotra, who will be seen sharing screen space with Manoj Bajpayee in “Aiyaary”, says the National Award winning actor is amazing and a team player.
Sidharth Malhotra on Thursday treated his fans to a question and answer session over Twitter.
A user asked the “Student Of The Year” actor about his experience working with Manoj in “Aiyaary”.
Sidharth replied: “He’s an amazing actor and a team player on set.”
“Aiyaary”, set in Delhi, London and Kashmir, revolves around two strong-minded Army officers having completely different views, yet right in their own ways. It is a real-life story based on the relationship between a mentor and a protege.
Presented by Plan C and Jayantilal Gada (Pen), the project is produced by Shital Bhatia, Dhaval Jayantilal Gada, Motion Picture Capital.
When asked about the development of the film, Sidharth replied: “Awesome. Excited to show it in a few months.”
Sidharth, 32, also described his “Brothers” co-star Akshay Kumar as his “brother from another mother.”(IANS)
A 47-year-old Indian-origin doctor in east London was charged with 118 sex offences, including one assault on a child under 13
Shah is out on bail and is due to appear on August 31 at Barkingside Magistrates’ Court in London
The charges announced today follow a long-running investigation into Shah, who has been bailed several times after first being arrested in 2013
London, August 3, 2017: A 47-year-old Indian-origin doctor in east London was on Thursday charged with 118 sex offenses, including one assault on a child under 13, by the Scotland Yard.
Dr Manish Shah, from Brunel Close in Romford area of the city, is accused of 65 counts of assault by penetration and 52 allegations of sexual assault, the Metropolitan Police said.
The doctor is also charged with one count of sexual assault on a child under the age of 13.
“Manish Shah has been charged with 65 assault by penetration, contrary to Section 2 of the Sexual Offences Act 2003, 52 sexual assault, contrary to Section 3 of the Sexual Offences Act 2003, and 1 sexual assault on a child under 13 years, contrary to Section 7 of the Sexual Offences Act 2003,” the Met Police said in a statement today.
Shah is out on bail and is due to appear on August 31 at Barkingside Magistrates’ Court in London.
Scientists developed a medical adhesive inspired by slug slime
The surgical glue is said to be strong, non-toxic and the best replacement to sutures and staples for healing wounds
The first such experiment was inspired by the sticking properties of underwater mussels
LONDON, July 31, 2017:Scientists have developed an experimental surgical glue inspired by the mucus secreted by slugs that could offer an alternative to sutures and staples for closing wounds.
While some medical glues already exist, they often adhere weakly, are not particularly flexible and frequently cannot be used in very wet conditions.
To get around those problems, a group of scientists from Harvard and other research centers decided to learn from slugs, which — as well as making slime to glide on — can produce extremely adhesive mucus as a defense mechanism.
The slugs’ trick is to generate a substance that not only forms strong bonds on wet surfaces but also has a matrix that dissipates energy at the point of adhesion, making it highly flexible.
The man-made version of this tough adhesive is based on the same principles and in a series of experiments reported in the journal Science on Thursday it was shown to adhere strongly to pig skin, cartilage, tissue and organs. It also proved nontoxic to human cells.
In one test, the new glue was used to close a wound in a blood-covered pig’s heart and successfully maintained a leak-free seal after the heart was inflated and deflated tens of thousands of times.
In another case it was applied to a laceration in a rat’s liver and performed just as well as a hemostat, a surgical tool often used in operations to control bleeding.
“There are a variety of potential uses and in some settings this could replace sutures and staples, which can cause damage and be difficult to place in certain situations,” said researcher David Mooney, professor of bioengineering at Harvard.
Mooney and colleagues envisage the new adhesive will be made in sheets and cut to size, although they have also developed an injected version for closing deep wounds. The injection would be hardened using ultraviolet light, like dental fillings.
It is not the first time that scientists have taken inspiration from nature to devise a better medical adhesive.
Four years ago, another research group developed a glue inspired by the underwater sticking properties of mussels, but Mooney thinks slugs win hands-down in terms of stickiness and flexibility.
The scientists are applying for patents, although it will require a commercial company to then license the technology and take it into the next phase of human clinical trials. (VOA)